Vaxart, Inc. (OTCQX: VXRT) announced that the European Patent Office granted the company European Patent No. 3791859, published Aug. 26, 2026, covering key aspects of its oral recombinant norovirus vaccine candidate.

The patent provides intellectual property protection through at least 2036 across 13 European jurisdictions, including Germany, France, Italy, Spain, and the United Kingdom. Additional countries where the patent will be validated include Austria, Belgium, Denmark, Ireland, Netherlands, Norway, Sweden, and Switzerland.

The patent covers elements of Vaxart's pill-based vaccine delivery technology, which the company describes as room-temperature stable and needle-free.

"Securing this patent expands our global intellectual property portfolio and secures additional protection of our norovirus asset for Europe through at least 2036," said Steven Lo, Chief Executive Officer of Vaxart.

Vaxart is a clinical-stage biotechnology company based in South San Francisco, California. Its development programs include oral pill vaccines targeting coronavirus, norovirus, and influenza, as well as a therapeutic vaccine for human papillomavirus.